leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2324252627282930313233...235236»
  • ||||||||||  Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
    Trial completion date, Trial primary completion date:  AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=104, Recruiting, 
    Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Oct 2022 --> Dec 2024
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Review, Journal, Metastases:  Preoperative Strategies for Locally Advanced Colon Cancer. (Pubmed Central) -  Feb 13, 2024   
    Patients with cT4 LACC, whether stage II or III, have a substantial risk of recurrence despite adjuvant fluoropyrimidine plus oxaliplatin chemotherapy...Clinical trials of neoadjuvant therapy for LACC are of great interest and should provide training for radiologists to identify eligible patients. Results are anticipated from multiple ongoing trials of neoadjuvant chemotherapy, immunotherapy, and targeted therapy for pMMR LACC and immunotherapy for dMMR LACC.
  • ||||||||||  pegvorhyaluronidase alfa (PEGPH20) / Halozyme
    Trial completion, Metastases:  S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Feb 9, 2024   
    P1/2,  N=126, Completed, 
    (4) The safety and moderate efficacy of nivolumab plus mFOLFOX6 were suggested even in AGC patients with severe peritoneal metastasis. Active, not recruiting --> Completed
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Retrospective data, Journal:  ASO Visual Abstract: In (Pubmed Central) -  Feb 8, 2024   
    Therefore, serum CEA may be a useful tool for decision making at both initial staging and time of restaging in patients with non-elevated CA19-9. No abstract available
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment open, Trial initiation date, Mismatch repair, Metastases:  Safety and Efficacy of PD-1  (clinicaltrials.gov) -  Feb 7, 2024   
    P2,  N=17, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> May 2022
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal, Metastases:  Long-Term Survival of a Patient with Advanced Antral Gastric Cancer Successfully Treated with Multidisciplinary Therapy (Pubmed Central) -  Feb 6, 2024   
    Subsequently, 7 courses of paclitaxel plus ramucirumab(PTX plus Rmab)therapy and 10 courses of nivolumab therapy were administered...After 16 courses of irinotecan therapy, CT showed a marked shrinkage in the size of the lymph node. The patient is currently alive with no signs of recurrence for 5 years, ie, since the initiation of the multidisciplinary therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Surgery:  Brain Metastasis Following Conversion Surgery for Sigmoid Colon Cancer-A Case Report (Pubmed Central) -  Feb 6, 2024   
    Subsequently, a combination regimen of capecitabine plus oxaliplatin plus bevacizumab was administered...Following the conversion surgery, he was administered the adjuvant chemotherapy regimen of uracil-tegafur plus Leucovorin...Contrast-enhanced magnetic resonance imaging revealed multiple brain metastases. Thus, we should be mindful of the possibility of brain metastasis in cases of unresectable colon cancer showing satisfactory response to chemotherapy with an indication of conversion surgery.
  • ||||||||||  Journal, Metastases:  A Case of Advanced Recurrent Rectal Cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug (Pubmed Central) -  Feb 6, 2024   
    Based on the findings of molecular and pathological examinations(RAS: wild type; BRAF: wild type; MSI: negative; HER2: negative), the following chemotherapy regimens were administered: first-line, FOLFIRI plus panitumumab(PANI); second-line, mFOLFOX6; third-line, trifluridine/tipiracil; fourth- line, regorafenib...Therefore, rechallenge therapy with anti-epidermal growth factor receptor(EGFR)drugs, cetuximab(CET)and irinotecan(IRI), was administered 13 months after the final course of FOLFIRI plus PANI treatment. After 4 courses of CET plus IRI, the size of the 2 metastatic tumors markedly decreased and his tumor marker levels normalized.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Surgery:  A Case of Conversion Surgery after Chemotherapy for Unresectable Liver Metastasis of Rectal Cancer (Pubmed Central) -  Feb 6, 2024   
    We determined that the liver metastases were unresectable and initiated FOLFOXIRI plus panitumumab treatment...Intraoperatively, it was determined that preservation of S7 Glisson was possible and blood flow preservation in the S7 region was feasible, and an anterior segment hepatic resection(S5-6-8)and lateral segment hepatic partial resection(S2/3)were performed. She was discharged on the 18th day and has been under outpatient observation 12 months after hepatectomy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, MSi-H Biomarker, PD(L)-1 Biomarker:  A Case of MSI-High Sigmoid Colon Cancer in Which Long-Term Survival Was Achieved by Pembrolizumab for Recurrent Lesions Resistant to Conventional Chemotherapy (Pubmed Central) -  Feb 6, 2024   
    The patient underwent sigmoidectomy with D3 lymph node dissection and partial bladder resection for sigmoid colon cancer(cT4bN1M0, cStage ?a), after preoperative chemotherapy with mFOLFOX plus panitumumab, and FOLFOXIRI plus bevacizumab...Although he was treated with FOLFIRI plus ramucirumab or aflibercept, resulted in progression of disease, then he received trifluridine tipiracil hydrochloride plus bevacizumab...He has received pembrolizumab for 4 years without another recurrence. Here, we report a case of MSI-high sigmoid colon cancer in which long-term survival was achieved by pembrolizumab for recurrent lesions resistant to conventional chemotherapy.
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal, Machine learning:  Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer. (Pubmed Central) -  Feb 5, 2024   
    The COLOXIS model is predictive of oxaliplatin benefits in the CC adjuvant setting. The results provide evidence supporting a change in CC adjuvant therapy: reserve oxaliplatin only for COLOXIS+ patients, but further investigation is warranted.
  • ||||||||||  Dissecting and quantifying pancreatic cancer plasticity using single-cell multiomics, lineage tracing and functional genomics reveals novel mediators of therapy resistance (Ballroom 6 CF - Upper Level - Convention Center) -  Feb 5, 2024 - Abstract #AACR2024AACR_1001;    
    P2
    This suggests a role for these TFs in enabling plasticity and facilitating state transitions.To study the effect of plasticity in treatment resistance, we treated four barcoded cell lines with the first-line chemotherapy combination FOLFIRINOX (5-fluorouracil, oxaliplatin and SN-38, the active metabolite of irinotecan) or targeted therapy and performed scSeq yielding over 600,00 single-cell transcriptomic profiles...We found the intermediate states were enriched in expression of our proposed plasticity factors, and importantly high expression of these factors in baseline samples correlated with a redistribution of states in follow-up biopsies.Our efforts define a robust experimental and quantitative framework for studying tumor cell plasticity in patient-derived model systems with validation in human patient samples using single-cell and spatial transcriptomics. Collectively, we nominate several regulators that alter the propensity of EMP in PDAC, thus posing a paradigm whereby perturbations may be used to homogenize tumor populations towards treatment-sensitive phenotypes for combination therapy.